Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Moodys
Daiichi Sankyo
US Department of Justice
Chinese Patent Office
Citi
Harvard Business School
Express Scripts
Healthtrust
Dow
UBS

Generated: February 24, 2018

DrugPatentWatch Database Preview

SIGNIFOR LAR Drug Profile

« Back to Dashboard

Summary for SIGNIFOR LAR
International Patents:123
US Patents:4
Applicants:1
NDAs:1
Suppliers / Packagers: 1
Bulk Api Vendors: 8
Clinical Trials: 5
Patent Applications: 29
Drug Prices:see details
DailyMed Link:SIGNIFOR LAR at DailyMed
Drug patent expirations by year for SIGNIFOR LAR

US Patents and Regulatory Information for SIGNIFOR LAR

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Novartis Pharms Corp SIGNIFOR LAR pasireotide pamoate POWDER;INTRAMUSCULAR 203255-001 Dec 15, 2014 RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Novartis Pharms Corp SIGNIFOR LAR pasireotide pamoate POWDER;INTRAMUSCULAR 203255-002 Dec 15, 2014 RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Novartis Pharms Corp SIGNIFOR LAR pasireotide pamoate POWDER;INTRAMUSCULAR 203255-001 Dec 15, 2014 RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y Y ➤ Try a Free Trial
Novartis Pharms Corp SIGNIFOR LAR pasireotide pamoate POWDER;INTRAMUSCULAR 203255-003 Dec 15, 2014 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Novartis Pharms Corp SIGNIFOR LAR pasireotide pamoate POWDER;INTRAMUSCULAR 203255-002 Dec 15, 2014 RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y Y ➤ Try a Free Trial
Novartis Pharms Corp SIGNIFOR LAR pasireotide pamoate POWDER;INTRAMUSCULAR 203255-003 Dec 15, 2014 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y Y ➤ Try a Free Trial
Novartis Pharms Corp SIGNIFOR LAR pasireotide pamoate POWDER;INTRAMUSCULAR 203255-001 Dec 15, 2014 RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Novartis Pharms Corp SIGNIFOR LAR pasireotide pamoate POWDER;INTRAMUSCULAR 203255-001 Dec 15, 2014 RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Novartis Pharms Corp SIGNIFOR LAR pasireotide pamoate POWDER;INTRAMUSCULAR 203255-002 Dec 15, 2014 RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Novartis Pharms Corp SIGNIFOR LAR pasireotide pamoate POWDER;INTRAMUSCULAR 203255-001 Dec 15, 2014 RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for SIGNIFOR LAR

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Novartis Pharms Corp SIGNIFOR LAR pasireotide pamoate POWDER;INTRAMUSCULAR 203255-001 Dec 15, 2014 ➤ Try a Free Trial ➤ Try a Free Trial
Novartis Pharms Corp SIGNIFOR LAR pasireotide pamoate POWDER;INTRAMUSCULAR 203255-002 Dec 15, 2014 ➤ Try a Free Trial ➤ Try a Free Trial
Novartis Pharms Corp SIGNIFOR LAR pasireotide pamoate POWDER;INTRAMUSCULAR 203255-003 Dec 15, 2014 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents for SIGNIFOR LAR

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,939,625 Somatostatin analogues ➤ Try a Free Trial
9,035,021 Somatostatin analogues ➤ Try a Free Trial
8,188,037 Microparticles comprising somatostatin analogues ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents for SIGNIFOR LAR

Supplementary Protection Certificates for SIGNIFOR LAR

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C/GB12/030 United Kingdom ➤ Try a Free Trial PRODUCT NAME: CYCLO((4R)-4-(2-AMINOETHYLCARBAMOYLOXY)-L-PROLYL-L-PHENYLGLYCYL-D-TRYPTOPHYL-L-LYSYL-4-O-BENZYL-L-TYROSYL-L-PHENYLALANYL-)), PASIREOTIDE, OR SALTS THEREOF; REGISTERED: UK EU/1/12/753/001-012 20120424
00716 Netherlands ➤ Try a Free Trial PRODUCT NAME: PASIREOTIDE OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN OF EEN HYDRAAT DAARVAN; REGISTRATION NO/DATE: EU/1/12/753 20141119
12/027 Ireland ➤ Try a Free Trial PRODUCT NAME: PASIREOTIDE OR A SALT OR COMPLEX THEREOF; REGISTRATION NO/DATE: EU/1/12/753/001-EU/1/12/753/012 20120424
2012 00024 Denmark ➤ Try a Free Trial PRODUCT NAME: PASIREOTID OG FARMACEUTISK ACCEPTABLE SALTE DERAF, HERUNDER PASIREOTIDDIASPARTAT; REG. NO/DATE: EU/1/12/753/001-012 20120424
C0041 France ➤ Try a Free Trial PRODUCT NAME: CYCLO((4R)-4(2-AMINOETHYLCARBAMOYLOXY)-L-PROLYL-L-PHENYLGLYCYL-D-TRYPTOPHYL-L-LYSYL-4-O-BENZYL-L-TYROSYL-L-PHENYLALANYL-) : PASIREOTIDE, OU SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI; REGISTRATION NO/DATE: EU/1/12/753/001 20120424
2015 00026 Denmark ➤ Try a Free Trial PRODUCT NAME: PASIREOTID ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF ELLER ET HVILKET SOM HELST HYDRAT DERAF, HERUNDER PASIREOTIDDIASPARTAT; REG. NO/DATE: EU/1/12/753, C(2014)8916 20141121
1307486/01 Switzerland ➤ Try a Free Trial PRODUCT NAME: PASIREOTID; REGISTRATION NO/DATE: SWISSMEDIC 61254 02.11.2012
8 Finland ➤ Try a Free Trial
90022-1 Sweden ➤ Try a Free Trial PRODUCT NAME: PASIREOTID; REG. NO/DATE: EU/1/12/753/001 20120424
701 Luxembourg ➤ Try a Free Trial PRODUCT NAME: PASIREOTIDE OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE QUI EN DERIVE OU UN HYDRATE QUI EN DERIVE . FIRST REGISTRATION: 20141121
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Chinese Patent Office
Cantor Fitzgerald
Teva
Federal Trade Commission
Boehringer Ingelheim
Harvard Business School
AstraZeneca
Baxter
Covington

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot